Amneal Pharmaceuticals, Inc. (AMRX)

NASDAQ: AMRX · USD

$21.1

-0.32 (-1.5%)· Recorded snapshot

Market cap	7.4B
Revenue (ttm)	3.1B
Net income (ttm)	157.4M
EPS (ttm)	$0.48
Shares out	348.3M
P/E (trailing)	43.9x
P/E (forward)	21.0x
Volume	1,137,213
Beta	1.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.1B
Net income (ttm): 157.4M
EPS (ttm): $0.48
P/E (trailing): 43.9x
P/E (forward): 21.0x
Market cap: 7.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E21

P25 n/aP50 n/aP75 n/a

Trailing P/E43.9

P25 n/aP50 n/aP75 n/a

ROE613

P25 n/aP50 n/aP75 n/a

ROIC18.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AMRX indicators

Market & fundamental data

Available fields

254

Groups with data

Currency

USD

Showing 254 of 254 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001723128
Company name	Amneal Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	03168L105
Earnings date	2026-11-03
Earnings time	bmo
Employees	8,700
Employees change	400
Employees growth	4.82%
Enterprise value	$10B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2002
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US03168L1052
Last 10-K release date	2026-02-27
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$7.4B
Market cap category	Mid-Cap
Next earnings date	2026-11-03
Options	Yes
Price	$21.12
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AMRX
U.S. state	New Jersey
Website	https://www.amneal.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	22.23x
Earnings yield	2.28%
EV/Earnings	63.85x
EV/EBIT	20.29x
EV/EBITDA	14.57x
EV/FCF	120.9x
EV/Sales	3.22x
FCF / EV yield	0.83%
FCF yield	1.12%
Forward EV/Sales	3.09x
Forward P/E	20.98x
Forward P/S	2.28x
Graham number	1.05774
Graham upside	-95.01%
Industry forward P/E	13.87x
Industry P/E	173.94x
Lynch fair value	$12.02
Lynch upside	-43.33%
P/(FCF - SBC) ratio	155.6x
P/(OCF - SBC) ratio	44.73x
P/B ratio	207.32x
P/E ratio	43.92x
P/FCF ratio	88.89x
P/OCF ratio	36.79x
P/S ratio	2.37x
PEG ratio	2.37x
Price/EBITDA ratio	10.72x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.88%
EBITDA margin	22.11%
FCF margin	2.67%
Gross margin	39.81%
Operating margin	15.88%
Pretax margin	6.45%
Profit margin	5.05%
Profit per employee	$18,088
Profitable quarters	6
Profitable years	1
Revenue per employee	$358,339
ROA	8.6%
ROA (5Y)	4.94%
ROCE	17.11%
ROE	613.02%
ROIC	18.64%
ROIC (5Y)	10.03%
SBC / revenue	1.14%
Tax / revenue	-0.45%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	4,332%
EPS growth (Q)	157.14%
EPS growth (QoQ)	-5.26%
EPS growth 5Y	50.48%
EPS growth quarters	3
EPS growth years	3
FCF growth	-69.32%
FCF growth 3Y	-17.33%
FCF growth 5Y	-14.3%
Gross profit growth	16.22%
Gross profit growth (Q)	16.95%
Gross profit growth 3Y	14.83%
Gross profit growth 5Y	11.31%
Net income growth	4,562.61%
Net income growth (Q)	157.22%
Net income growth (QoQ)	-7.38%
Net income growth 5Y	76.35%
Net income growth quarters	7
Net income growth years	1
OCF growth	-42.81%
OCF growth 3Y	0.36%
OCF growth 5Y	-4.05%
Operating income growth	30.4%
Operating income growth (Q)	30.33%
Operating income growth 3Y	26.42%
Operating income growth 5Y	22.08%
Revenue growth	9.28%
Revenue growth (Q)	9.9%
Revenue growth (QoQ)	10.2%
Revenue growth 3Y	10.48%
Revenue growth 5Y	8.67%
Revenue growth quarters	21
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-117.7M
Depreciation and amortization	$194.3M
EBIT	$495.1M
EBITDA	$689.4M
EPS	$0.48
FCF per share	$0.24
Financing cash flow	$69.6M
Free cash flow	$83.1M
Free cash flow minus SBC	$47.5M
Gross profit	$1.2B
Income taxes	$-14.1M
Investing cash flow	$-212.4M
Net borrowing	$228.3M
Net cash flow	$55.9M
Net income	$157.4M
Operating cash flow minus SBC	$165.1M
Operating income	$495.1M
Revenue	$3.1B
Stock-based compensation	$35.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.06
Book value per share	$0.10
Debt / EBITDA	3.94
Debt / equity	23.87
Debt / FCF	33.59
Goodwill	$593.5M
Interest coverage	2.18
Long-term assets	$1.8B
Long-term liabilities	$2.8B
Net cash (debt)	$-2.7B
Net cash / market cap	-36.01%
Net debt / EBITDA	3.86
Net debt / equity	22.74
Net debt / FCF	32.01
Piotroski F-Score	7
Property, plant and equipment	$567.3M
Shareholders' equity	$117M
Tangible book value	$-1.1B
Tangible book value per share	$-3.60
Total assets	$3.8B
Total cash	$131.4M
Total debt	$2.8B
Total liabilities	$3.7B
WACC	9.71%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.87
Current assets	$1.9B
Current liabilities	$883.2M
Current ratio	2.2
Inventory turnover	2.92
Net working capital	$1.1B
Quick ratio	1.37
Working capital	$1.1B
Working capital turnover	4.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.48%
Dividend yield	0%
Shareholder yield	-3.48%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$16.35
1D price change	-1.49%
1M price change	6.83%
1M total return	6.83%
1W price change	4.55%
1W total return	4.55%
1Y price change	106.05%
1Y return CAGR	106.15%
1Y total return	106.05%
20-day SMA	$20.05
200-day SMA	$15.66
3M price change	16.75%
3M total return	16.75%
3Y price change	460.21%
3Y return CAGR	77.58%
3Y total return	460.21%
50-day SMA	$18.98
50-day SMA vs 200-day SMA	50over200
52-week high	$21.65
52-week high date	2026-10-28
52-week low	$9.99
52-week low date	2025-10-30
5Y price change	295.51%
5Y return CAGR	31.66%
5Y total return	295.51%
6M price change	68.02%
6M total return	68.02%
All-time high	$24.48
All-time high date	2018-08-22
All-time low	$1.24
All-time low date	2023-03-28
Average true range (ATR)	$0.66
Average volume	3.5M
Beta (1Y)	0.67
Beta (2Y)	0.75
Beta (5Y)	1.22
Change from 52-week high	-2.58%
Change from 52-week low	111.41%
Change from all-time high	-13.73%
Change from all-time low	1,603.23%
Change from open	-0.98%
Day's gap	-0.51%
Dollar volume	$24M
High price	$21.65
Low price	$21.08
Monthly RSI	82.4
Open price	$21.33
Position in 52-week range	7.02%
Premarket change	0.47%
Premarket close	$21.44
Premarket price	$21.54
Premarket volume	4.5K
Previous close	$21.44
Price vs 150-day SMA	29.21%
Price vs 20-day SMA	5.34%
Price vs 200-day SMA	34.87%
Price vs 50-day SMA	11.25%
Relative volume	0.33
RSI	64.53
Sharpe ratio	2.09
Sharpe ratio (3Y)	1.66
Sharpe ratio (5Y)	0.69
Sortino ratio	3.77
Sortino ratio (3Y)	3.11
Sortino ratio (5Y)	1.2
Volume	1.1M
Weekly RSI	72.34
YTD price change	67.62%
YTD total return	67.62%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	215.2M
Float percentage	61.79%
Shares change (QoQ)	-0.25%
Shares change (YoY)	3.48%
Shares held by insiders	38.19%
Shares held by institutions	48.54%
Shares outstanding	348.3M
Short % of float	6.54%
Short % of shares	4.04%
Short ratio	4.1 days

Deeper analysis on AMRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AMRX report

Is a complete AMRX research report available?

No complete published report is available for Amneal Pharmaceuticals, Inc. (AMRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Amneal Pharmaceuticals, Inc. (AMRX)

Price

Financial snapshot

Fair-value bridge

Latest news · AMRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AMRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AMRX

Frequently asked questions